Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:NVS
Previous Symbol
CUSIPN/A
Phone41-61-324-1111
Debt
Debt-to-Equity Ratio0.29
Current Ratio1.20
Quick Ratio0.96
Price-To-Earnings
Trailing P/E Ratio18.02
Forward P/E Ratio16.83
P/E Growth1.93
Sales & Book Value
Annual Sales$49.11 billion
Price / Sales4.09
Cash Flow$7.5333 per share
Price / Cash Flow11.55
Book Value$32.03 per share
Price / Book2.72
Profitability
EPS (Most Recent Fiscal Year)$4.81
Net Income$7.70 billion
Net Margins25.98%
Return on Equity15.81%
Return on Assets8.58%
Miscellaneous
Employees121,597
Outstanding Shares2,310,000,000
Market Cap$201.15 billion
OptionableOptionable
Novartis (NYSE:NVS) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How will Novartis' stock buyback program work?
Novartis announced that its Board of Directors has approved a stock buyback program on Saturday, April 8th 2017, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its shares are undervalued.
How were Novartis' earnings last quarter?
Novartis AG (NYSE:NVS) released its quarterly earnings results on Thursday, October, 18th. The company reported $1.32 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.31 by $0.01. The firm earned $12.78 billion during the quarter, compared to the consensus estimate of $12.88 billion. Novartis had a return on equity of 15.81% and a net margin of 25.98%. The company's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.29 EPS. View Novartis' Earnings History.
When is Novartis' next earnings date?
What price target have analysts set for NVS?
16 brokerages have issued 12 month price targets for Novartis' shares. Their predictions range from $74.71 to $88.03. On average, they anticipate Novartis' share price to reach $81.37 in the next year. This suggests that the stock has a possible downside of 6.1%. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 1 sell rating, 9 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Has Novartis been receiving favorable news coverage?
News coverage about NVS stock has been trending very positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novartis earned a media sentiment score of 3.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Are investors shorting Novartis?
Novartis saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,932,071 shares, an increase of 109.0% from the October 15th total of 2,360,402 shares. Based on an average daily volume of 3,830,632 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.2% of the company's stock are short sold. View Novartis' Current Options Chain.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
- Mr. Harry Kirsch, Chief Financial Officer (Age 53)
- Mr. Steven Baert, Head of HR (Age 44)
- Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)
- Dr. James E. Bradner M.D., Pres of Novartis Institutes for Biomedical Research (Age 46)
Who are Novartis' major shareholders?
Novartis' stock is owned by many different of institutional and retail investors. Top institutional investors include Dodge & Cox (1.91%), Primecap Management Co. CA (0.96%), Franklin Resources Inc. (0.65%), Brown Brothers Harriman & Co. (0.32%), Fisher Asset Management LLC (0.32%) and Loomis Sayles & Co. L P (0.32%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.
Which major investors are selling Novartis stock?
NVS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Franklin Resources Inc., Brown Brothers Harriman & Co., Deutsche Bank AG, Marshall Wace North America L.P., BlackRock Inc., Manning & Napier Group LLC and Sei Investments Co.. View Insider Buying and Selling for Novartis.
Which major investors are buying Novartis stock?
NVS stock was purchased by a variety of institutional investors in the last quarter, including Matthew Goff Investment Advisor LLC, Point72 Asset Management L.P., Eagle Asset Management Inc., Janus Henderson Group PLC, Bank of New York Mellon Corp, Dodge & Cox, Rockefeller Capital Management L.P. and The Manufacturers Life Insurance Company . Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.
How do I buy shares of Novartis?
Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novartis' stock price today?
One share of NVS stock can currently be purchased for approximately $86.61.
How big of a company is Novartis?
Novartis has a market capitalization of $201.15 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]
MarketBeat Community Rating for Novartis (NYSE NVS)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
